Search

Objective: The real-world INFORM study analyzed sociodemographics, treatment patterns and clinical outcomes for patients with newly diagnosed advanced epithelial ovarian cancer (EOC) in Australia, South Korea (S.Korea) and Taiwan preceding incorporation of poly(ADPribose) polymerase inhibitors into clinical practice. Methods: Retrospective data from patients diagnosed with EOC (high-grade serous EOC for Taiwan) between January 2014 and December 2018 with =12 months follow-up from diagnosis were analyzed descriptively. Survival was evaluated by Kaplan-Meier with two-sided 95% confidence interval (CI). Results: Of the 987 patients (Australia, 223; S.Korea, 513; Taiwan, 251), 98% received platinum-based chemotherapy (CT). In S.Korea and Taiwan 76.0% and 78.9% respectively underwent primary cytoreductive surgery; in Australia, 56.5% had interval debulking surgery. Bevacizumab was included in primary/maintenance therapy for 22.4%, 14.6% and 6.8% of patients in Australia, S.Korea and Taiwan, respectively. Patients receiving bevacizumab were high-risk (reimbursement policy) and achieved similar real-world progression-free survival (PFS) compared with CT only. Overall, the median real-world PFS (months; 95% CI) was similar across Australia (16.0 [14.63-18.08]), S.Korea (17.7 [16.18-19.27]) and Taiwan (19.1 [17.56-22.29]). Conclusion: This study reveals poor prognosis despite differences in demographics and treatment patterns for patients with EOC across Asia-Pacific suggesting the need for biomarker-driven novel therapies to improve outcomes. [ABSTRACT FROM AUTHOR]

Total oxidisable precursor assay (TOP assay) can degrade and convert "unknown" per- and polyfluoroalkyl substances (PFAS) to detectable PFAS. However, the detailed degradation pathway is still not known, particularly when the TOP assay is applied to analyse complex samples such as aqueous film-forming foam (AFFF). To gain insights into the pathway and the effectiveness of the TOP assay, several "known" compounds are first tested as controls, including sodium dodecyl benzene sulphate (SDBS), perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS). Secondly, the test is expanded to several PFAS precursors such as 6:2 fluorotelomer sulfonate (6:2 FTS), 8:2 fluorotelomer sulfonate (8:2 FTS), and a cationic surfactant N-ethyl-N-(2-hydroxyethyl) perfluorooctyl sulfonamide (EtFOSE). Thirdly, the TOP assay is used to test "unknown" PFAS samples that have been previously used as AFFF in Australia. The degradation products are monitored, to compare the mass balance and propose the degradation pathway. While HPLC-MS/MS is typically employed to detect the individual TOP assay products, most of which are perfluoroalkyl carboxylic acids (PFCA), an app-based smartphone sensor can also provide semi-quantitative results as a sum. Overall, the results indicate the effectiveness of the TOP assay to assess the presence of PFAS precursors in the AFFF samples, with some variations in the end products. Recommendations for enhancement of the TOP assay are also provided. [Display omitted] • Insights on TOP assay using blank control, negative control, positive control and PFAS precursors. • FTS as indicator to suggest the TOP assay efficiency. • Variation on the end products, particularly for real sample such as AFFF. • Enhancement of TOP assay recommended. • Semi-quantitative test achieved by an app-based smartphone sensor, with help D-LPE to remove background. [ABSTRACT FROM AUTHOR]